Cancer cells appear to hijack a fundamental RNA processing mechanism through an unexpected pathway that could reshape therapeutic approaches. This discovery reveals how malignant cells manipulate their genetic instructions after DNA transcription, potentially explaining why certain cancers resist treatment.
Researchers identified that EZH2, a protein traditionally known for silencing genes through histone modification, directly interacts with ADAR1 enzymes that edit RNA molecules. This interaction occurs independently of EZH2's established methyltransferase function. By competing with another regulatory protein (ILF2) for ADAR1 binding, EZH2 redirects which RNA sequences undergo adenosine-to-inosine editing. When EZH2 levels drop, a specific ADAR1 variant accumulates in the cytoplasm, where it protects cancer-promoting RNA transcripts from degradation. Prostate cancer cells with depleted ADAR1 showed dramatically increased sensitivity to EZH2-targeting drugs.
This finding bridges two previously separate epigenetic control systems—histone modification and RNA editing—suggesting cancer's regulatory networks are more interconnected than recognized. The discovery has immediate clinical relevance since EZH2 inhibitors are already in therapeutic development. However, the research was conducted primarily in prostate cancer cell lines, limiting broader applicability. The mechanism's role across different cancer types and normal tissue contexts requires investigation. Most significantly, this work reveals that proteins can have completely distinct functions beyond their primary enzymatic activities, potentially explaining why single-target cancer therapies often fail. Understanding these dual regulatory roles may guide combination therapy strategies that simultaneously disrupt multiple cancer survival mechanisms.